Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, Sandhu MS, Jukema JW, Kastelein JJ, Hack CE, Khaw KT. Boekholdt SM, et al. Among authors: jukema jw. Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):839-46. doi: 10.1161/01.ATV.0000157933.19424.b7. Epub 2005 Feb 3. Arterioscler Thromb Vasc Biol. 2005. PMID: 15692105
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI, et al. Jukema JW, et al. Circulation. 1995 May 15;91(10):2528-40. doi: 10.1161/01.cir.91.10.2528. Circulation. 1995. PMID: 7743614 Clinical Trial.
Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group.
Jukema JW, Zwinderman AH, van Boven AJ, Reiber JH, Van der Laarse A, Lie KI, Bruschke AV. Jukema JW, et al. Arterioscler Thromb Vasc Biol. 1996 Mar;16(3):425-30. doi: 10.1161/01.atv.16.3.425. Arterioscler Thromb Vasc Biol. 1996. PMID: 8630669 Clinical Trial.
The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JH, Bruschke AV, Henneman JA, Molhoek GP, Bruin T, Jansen H, Gagné E, Hayden MR, Kastelein JJ. Jukema JW, et al. Circulation. 1996 Oct 15;94(8):1913-8. doi: 10.1161/01.cir.94.8.1913. Circulation. 1996. PMID: 8873668 Clinical Trial.
Thermolabile methylenetetrahydrofolate reductase in coronary artery disease.
Kluijtmans LA, Kastelein JJ, Lindemans J, Boers GH, Heil SG, Bruschke AV, Jukema JW, van den Heuvel LP, Trijbels FJ, Boerma GJ, Verheugt FW, Willems F, Blom HJ. Kluijtmans LA, et al. Among authors: jukema jw. Circulation. 1997 Oct 21;96(8):2573-7. doi: 10.1161/01.cir.96.8.2573. Circulation. 1997. PMID: 9355896
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ. Kuivenhoven JA, et al. Among authors: jukema jw. N Engl J Med. 1998 Jan 8;338(2):86-93. doi: 10.1056/NEJM199801083380203. N Engl J Med. 1998. PMID: 9420339 Free article. Clinical Trial.
-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group.
de Maat MP, Kastelein JJ, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B, Bruschke AV, Kluft C. de Maat MP, et al. Among authors: jukema jw. Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):265-71. doi: 10.1161/01.atv.18.2.265. Arterioscler Thromb Vasc Biol. 1998. PMID: 9484992 Review.
The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group.
Kastelein JJ, Groenemeyer BE, Hallman DM, Henderson H, Reymer PW, Gagné SE, Jansen H, Seidell JC, Kromhout D, Jukema JW, Bruschke AV, Boerwinkle E, Hayden MR. Kastelein JJ, et al. Among authors: jukema jw. Clin Genet. 1998 Jan;53(1):27-33. doi: 10.1034/j.1399-0004.1998.531530106.x. Clin Genet. 1998. PMID: 9550358
1,130 results